| The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis D Guh, W Zhang, N Bansback, Z Amarsi, CL Birmingham, A Anis BMC Public Health 9 (1), 88, 2009 | 5699 | 2009 |
| A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada F Xie, E Pullenayegum, K Gaebel, N Bansback, S Bryan, A Ohinmaa, ... Medical care 54 (1), 98-105, 2016 | 449 | 2016 |
| Obesity and overweight in Canada: an updated cost‐of‐illness study AH Anis, W Zhang, N Bansback, DP Guh, Z Amarsi, CL Birmingham Obesity Reviews 11 (1), 31-40, 2010 | 433 | 2010 |
| Measuring and valuing productivity loss due to poor health: A critical review W Zhang, N Bansback, AH Anis Social Science & Medicine, 2010 | 431 | 2010 |
| Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis W Zhang, N Bansback, A Boonen, A Young, A Singh, AH Anis Arthritis research & therapy 12 (5), R177, 2010 | 341 | 2010 |
| The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis EJ Mills, S Kanters, A Hagopian, N Bansback, J Nachega, M Alberton, ... BMJ 343, 2011 | 331 | 2011 |
| Using a discrete choice experiment to estimate health state utility values N Bansback, J Brazier, A Tsuchiya, A Anis Journal of Health Economics 31 (1), 306-318, 2012 | 321 | 2012 |
| Physician attitudes toward shared decision making: A systematic review S Pollard, N Bansback, S Bryan Patient education and counseling 98 (9), 1046-1057, 2015 | 302 | 2015 |
| Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis S Kanters, M Vitoria, M Doherty, ME Socias, N Ford, JI Forrest, E Popoff, ... The Lancet HIV 3 (11), e510-e520, 2016 | 273 | 2016 |
| Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies N Bansback, A Tsuchiya, J Brazier, A Anis PLoS ONE 7 (2), e31115, 2012 | 268 | 2012 |
| Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK A Brennan, N Bansback, A Reynolds, P Conway Rheumatology 43 (1), 62-72, 2004 | 217 | 2004 |
| The impact of age-related macular degeneration on health status utility values M Espallargues, CJ Czoski-Murray, NJ Bansback, J Carlton, GM Lewis, ... Investigative ophthalmology & visual science 46 (11), 4016-4023, 2005 | 199 | 2005 |
| Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis RM Nixon, N Bansback, A Brennan Statistics in medicine 26 (6), 1237-1254, 2007 | 194 | 2007 |
| Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden NJ Bansback, A Brennan, O Ghatnekar Annals of the rheumatic diseases 64 (7), 995-1002, 2005 | 162 | 2005 |
| Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry A Brennan, N Bansback, R Nixon, J Madan, M Harrison, K Watson, ... Rheumatology 46 (8), 1345-1354, 2007 | 149 | 2007 |
| Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents A Finckh, N Bansback, CA Marra, AH Anis, K Michaud, S Lubin, M White, ... Annals of internal medicine 151 (9), 612-621, 2009 | 142 | 2009 |
| Use of network meta-analysis in clinical guidelines S Kanters, N Ford, E Druyts, K Thorlund, EJ Mills, N Bansback Bulletin of the World Health Organization 94 (10), 782, 2016 | 140 | 2016 |
| Projecting the direct cost burden of osteoarthritis in Canada using a microsimulation model B Sharif, J Kopec, N Bansback, MM Rahman, WM Flanagan, H Wong, ... Osteoarthritis and Cartilage 23 (10), 1654-1663, 2015 | 140 | 2015 |
| The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons R Nixon, N Bansback, A Brennan Rheumatology 46 (7), 1140, 2007 | 140 | 2007 |
| Biologic drugs for rheumatoid arthritis in the medicare program: A cost‐effectiveness analysis AJ Wailoo, N Bansback, A Brennan, K Michaud, RM Nixon, F Wolfe Arthritis & Rheumatism 58 (4), 939-946, 2008 | 136 | 2008 |
Aslam H AnisSchool of Population and Public Health, University of British ColumbiaVerified email at ubc.ca
